ImmunityBio presented interim results from its phase 2 metastatic pancreatic cancer trial (QUILT 88) evaluating its NANT Cancer vaccine, comprising ImmunityBio’s IL-15 receptor agonist Anktiva…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.